Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Data as at: 15/03/2024
In
Objective
To achieve long-term capital growth by investing in biotechnology and other life sciences companies.
AIC sector
Management group
Schroder Investment Management
Company website
Launch date
06/05/1994
August
Domicile
United Kingdom
Fund manager
Ailsa Craig, Marek Poszepczynski
Dividend frequency
Semi-Annually
Wind-up provisions
The Association Articles of the company provide for Directors to put forward a proposal for the continuation of the company at the AGM at two-yearly intervals. The upcoming continuation vote is scheduled for the December 2023 AGM.
Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
---|---|---|---|---|---|---|---|---|
252.17 | 304.15 | 662.00 | 726.11 | -8.83 | 6 | 4.26 | Jul, Dec | 1.4 (31/08/2023) |
Scroll
Dividends
Dividends declared in last 12 months
Ex-Dividend date | Payment date | Dividend amount | Special dividend | Financial year |
---|---|---|---|---|
21/12/2023 | 26/01/2024 | 13.900 | No | 2024 |
27/07/2023 | 25/08/2023 | 14.200 | No | 2023 |
Scroll
Performance (%)
Return type | 1 year | 3 years | 5 years | 10 years | |
---|---|---|---|---|---|
International Biotechnology | Share price total return | 5.5 | -3.9 | 27.9 | 184.0 |
Biotechnology & Healthcare AIC sector | Share price total return | 2.9 | -22.2 | 1.9 | 112.2 |
Scroll
Share structure
Number of shares
38,092,407
3,291,410
Traded volumes (number of shares)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 36,658 | 1,381,265 | 12,652,813 | 83,216,560 |
Average | N/A | 65,775 | 50,011 | 65,940 |
Scroll
Traded values (m)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 0.24 | 9.30 | 80.85 | 571.85 |
Average | N/A | 0.44 | 0.32 | 0.45 |
Scroll
Trading details
Top holdings
Data as at : 31/01/2024
Investment | % of total assets |
---|---|
Vera Therapeutics Inc Class A | 6.2 |
Gilead Sciences Inc | 5.6 |
Sv Fund Vi Investment | 5.1 |
Cytokinetics Inc | 4.7 |
Supernus Pharmaceuticals Inc | 4.6 |
Amgen Inc | 4.3 |
Incyte Corp | 4.0 |
United Therapeutics Corp | 3.9 |
Biomarin Pharmaceutical Inc | 3.6 |
Scb Sholo211123b 19-Jan-2024 6.460000% 20-Feb-2024 | -10.6 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.